Rivaroxaban Viatris (previously Rivaroxaban Mylan) ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Blincyto ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Brilique ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

brilique

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombotska sredstva - brilique, propisana u suradnji s ацетилсалициловой kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata withacute koronarni sindrom (acs) ora priča infarkta miokarda (im) i visokim rizikom za razvoj атеротромботических eventbrilique, uvedene zajedno sa acetil salicilna kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata s анамнезом infarkta miokarda (im dogodio ne manje od godine) i visokim rizikom od razvoja događaja атеротромботических.

Obizur ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

obizur

baxalta innovations gmbh - susoctocog alfa - hemofilija a - antihemorrhagics - liječenje krvarenja epizoda u bolesnika s stečena hemofilija uzrokovane antitijela na faktor viii. obizur je indiciran kod odraslih osoba.

Visudyne ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

visudyne

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - Визудин indiciran za liječenje:odrasli s экссудативной (vlažna) senilne makularne degeneracije (amd) s pretežno klasične subfoveal хориоидальной неоваскуляризации (ХНВ); ili odrasli s subfoveal хориоидальной неоваскуляризации sekundarne patološkog kratkovidnosti.

Atixarso 60 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

atixarso 60 mg filmom obložene tablete

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - tikagrelor - filmom obložena tableta - 60 mg - urbroj: jedna filmom obložena tableta sadrži 60 mg tikagrelora

Atixarso 90 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

atixarso 90 mg filmom obložene tablete

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - tikagrelor - filmom obložena tableta - 90 mg - urbroj: jedna filmom obložena tableta sadrži 90 mg tikagrelora

Tilobrastil 60 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

tilobrastil 60 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - tikagrelor - filmom obložena tableta - 60 mg - urbroj: jedna filmom obložena tableta sadrži 60 mg tikagrelora